Considerations for distinguishing influenza-like illness from inhalational anthrax.
CDC has issued guidelines on the evaluation of persons with a history of exposure to Bacillus anthracis spores or who have an occupational or environmental risk for anthrax exposure. This notice describes the clinical evaluation of persons who are not known to be at increased risk for anthrax but who have symptoms of influenza-like illness (ILI). Clinicians evaluating persons with ILI should consider a combination of epidemiologic, clinical, and, if indicated, laboratory and radiographic test results to evaluate the likelihood that inhalational anthrax is the basis for ILI symptoms.
D000881:Anthrax / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology; D001408:Bacillus anthracis / Q000302:isolation & purification; D019411:Clinical Laboratory Techniques; D003937:Diagnosis, Differential; D006801:Humans; D007251:Influenza, Human / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology; D009975:Orthomyxoviridae / Q000302:isolation & purification; D012136:Respiratory Syncytial Viruses / Q000302:isolation & purification; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000453:epidemiology / Q000382:microbiology* / Q000503:physiopathology; D014481:United States / Q000453:epidemiology